Asco 2023 – Pfizer pushes forward in drug-resistant breast cancer
While Ibrance has been bested by class rivals, Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance – though it is not alone.
Asco 2023 preview – a microcap winner
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Blueprint for disappointment
Ayvakit hits in its pivotal indolent systemic mastocytosis trial, but a dwindling effect size reignites commercial concerns.
Unpacking Royalty Pharma
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
